High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Reason given: Funding ceased before all specimen collection and analysis could be completed
Key facts
- Where
- Los Angeles, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Cedars-Sinai Medical CenterLos Angeles, United StatesNo longer taking part
Trial details
- Who runs it
- Alessandro D'Agnolo
- Trial code
- NCT04461509
- Record updated
- 22 July 2026
- Original description
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI in patients considered candidates for focal HIFU.Read full original descriptionShow less
High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI in patients considered candidates for focal HIFU.
Inclusion: Biopsy consisting of ≥ 10 tissue cores sampled; PSA <20 ng/mL (for HIFU arm only); cT1-cT2c; Either overall Gleason score > 7 with Gleason grade 4 or 5 component localized to one lobe (i.e. right or left) OR overall Gleason score 6 with > half of systematic biopsy cores positive and > 50% of core involvement in at least one core (for HIFU arm only); Patient considering focal HIFU therapy or robotic radical prostatectomy.
Exclusion: Previous local therapy for prostate cancer; Any other condition which, in the investigator's option, may make the patient a poor candidate for participation in a clinical trial; Estimated glomerular filtration rate (GFR) <15 mL/min/1.73 m2; Inability to receive PET tracer; Inability to receive MRI.